0000950170-23-018790.txt : 20230508 0000950170-23-018790.hdr.sgml : 20230508 20230508160606 ACCESSION NUMBER: 0000950170-23-018790 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230508 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230508 DATE AS OF CHANGE: 20230508 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 23897731 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 8-K 1 crsp-20230508.htm 8-K 8-K
false00-0000000000167441600016744162023-05-082023-05-08

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 8, 2023

 

 

CRISPR THERAPEUTICS AG

(Exact name of registrant as specified in its charter)

 

 

Switzerland

001-37923

Not Applicable

(State or other jurisdiction
of incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

Baarerstrasse 14

 

6300 Zug, Switzerland

 

Not Applicable

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: 41 (0)41 561 32 77

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Shares, nominal value CHF 0.03

 

CRSP

 

The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2023, CRISPR Therapeutics AG announced its financial results for the quarter ended March 31, 2023 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit
No.

 

Description

 

 

99.1

Press Release by CRISPR Therapeutics AG, dated May 8, 2023

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

CRISPR Therapeutics AG

 

 

 

 

Date:

May 8, 2023

By:

/s/ Samarth Kulkarni

 

 

 

Samarth Kulkarni, Ph.D.
Chief Executive Officer

 

 

 

 EX-99 2 crsp-ex99_1.htm EX-99.1 EX-99

Exhibit 99.1

 

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)-

-EU and U.K. submissions validated by European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA); exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA-

-Enrollment and dosing ongoing for CTX110®, targeting CD19+ B-cell malignancies, and CTX130™, targeting CD70 for the treatment of T cell lymphomas-

-Initiated clinical trials for next generation CAR T candidates, CTX112™ targeting CD19+ B-cell malignancies and CTX131™, targeting CD70+ solid tumors-

-Enrollment and dosing ongoing in a Phase 1/2 clinical trial of VCTX211™ for the treatment of Type 1 Diabetes (T1D)-

 

-Continues to advance its lead in vivo program, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) into clinical trials this year-

 

ZUG, Switzerland and BOSTON, Mass., May 8, 2023 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the first quarter ended March 31, 2023.

“In the first quarter of 2023, we continued strong momentum across our portfolio. We and our partner Vertex have now completed regulatory submissions for exa-cel in the United States, European Union and United Kingdom, positioning exa-cel to potentially become the first approved CRISPR-based therapy in the world, a remarkable pace of progress considering the discovery of the CRISPR platform took place a little more than a decade ago,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “In parallel, we continue to drive our portfolio programs, including the initiation of clinical trials for our next-generation CAR T candidates, CTX112 and CTX131. In addition, we expect to advance CTX310, our lead in vivo program targeting ANGPTL3, into clinical trials later this year. We are well-positioned to drive towards our mission of bringing transformative and potentially curative therapies to patients in need.”

 

Recent Highlights and Outlook

•
Hemoglobinopathies
o
In April, CRISPR Therapeutics and Vertex Pharmaceuticals announced the completion of the rolling submissions of their biologics licensing applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel), formerly known as CTX001™, for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The BLAs include requests for Priority Review, which, if granted, would shorten the FDA’s review of the application to eight months from the time of submission versus a standard review timeline of 12 months. In the U.S., exa-cel has been granted Fast Track, Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug (ODD) and Rare Pediatric Disease designations.
o
In December 2022, CRISPR Therapeutics and Vertex Pharmaceuticals completed regulatory submissions for exa-cel with the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the EU and the U.K., respectively. Both the EMA and the MHRA have validated the Marketing Authorization Applications (MAAs), indicating acceptance of the marketing applications and initiation of the review. Exa-cel has been granted Priority Medicines (PRIME) and ODD in the EU. In the U.K., exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.
o
The Phase 1/2/3 CLIMB-111 and CLIMB-121 studies and the CLIMB-131 long-term follow-up study are ongoing in patients 12 years of age and older.
o
Two additional Phase 3 studies of exa-cel in pediatric patients with TDT and SCD continue to enroll patients.
o
CRISPR Therapeutics continues to advance its anti-CD117 (c-Kit) antibody-drug conjugate (ADC), its internal targeted conditioning program, in pre-clinical studies. This targeted conditioning agent has the potential to significantly expand the patient population that can benefit from exa-cel.

 

•
Immuno-Oncology
o
CRISPR Therapeutics continues to enroll and dose patients in a Phase 2 single-arm potentially registrational clinical trial of CTX110®, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR T) investigational therapy targeting CD19+ B-cell malignancies.
o
CRISPR Therapeutics continues to enroll and dose patients in the Company’s ongoing Phase 1 COBALT™-LYM trial evaluating the safety and efficacy of CTX130™, its wholly-owned allogeneic CAR T cell therapy targeting CD70 for the treatment of relapsed or refractory T cell malignancies. Based on preliminary data, CTX130 was granted the RMAT designation by the FDA. Given the encouraging early results, the Company continues to advance CTX130 for these difficult-to-treat T cell lymphomas in its COBALT-LYM trial.
o
CRISPR Therapeutics has begun enrolling patients in the CTX112™ clinical trial, its next generation CAR T candidate targeting CD19+ B-cell malignancies, following the previously-announced clearance of its Investigational New Drug (IND) application by the FDA. CTX112 incorporates the edits in CTX110 plus additional edits to the genes encoding Regnase-1 and TGFBRII, which have been shown to increase the potency of the CAR T cells in pre-clinical studies. CRISPR Therapeutics has also initiated a clinical trial for CTX131™, its next generation CAR T cell candidate targeting CD70, following clearance of its IND application by the FDA in February 2023. CTX131 incorporates the edits in CTX130 plus additional edits to the genes encoding Regnase-1 and TGFBRII, which have been shown to increase the potency of the CAR T cells in pre-clinical studies.
o
In April, CRISPR Therapeutics presented an oral presentation of preclinical data at the New Drugs on the Horizon Session (Part 1) in the American Association for Cancer Research (AACR) 2023 Annual Meeting for CTX112 and CTX131, entitled CTX112 and CTX131: Next-generation CRISPR/Cas9-engineered allogeneic CAR T cells incorporating novel edits that increase potency and efficacy in the treatment of lymphoid and solid tumors.
•
Regenerative Medicine and In Vivo
o
In March, CRISPR Therapeutics and Vertex and CRISPR Therapeutics and ViaCyte, Inc., which was acquired by Vertex in 2022, entered into agreements relating to the research, development, manufacturing and commercialization of therapeutic products in the diabetes field, including a new non-exclusive licensing agreement for the use of CRISPR Therapeutics’ CRISPR/Cas9 gene editing technology to accelerate the development of Vertex’s hypoimmune cell therapies for type 1 diabetes (T1D). In connection with entering into the agreements with Vertex and ViaCyte, CRISPR Therapeutics received $100 million up-front from Vertex. CRISPR Therapeutics will be eligible for up to an additional $230 million in research and development milestones and receive royalties on any future products resulting from the non-exclusive licensing agreement. CRISPR Therapeutics and ViaCyte continue to collaborate on their existing gene-edited allogeneic stem cell therapies, using ViaCyte cells, for the treatment of diabetes under the terms of their collaboration.
o
Based upon ongoing progress with its in vivo approaches for liver gene editing, CRISPR Therapeutics expects to move multiple programs utilizing in vivo approaches into the clinic within the next 12 months. The Company continues to advance its lead in vivo program, CTX310™, targeting angiopoietin-related protein 3 (ANGPTL3) into clinical trials this year.
•
Other Corporate Matters
o
In March, CRISPR Therapeutics announced the appointment of Raju Prasad, Ph.D., as Chief Financial Officer. He joined CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies.
o
In March, CRISPR Therapeutics announced the departure of Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, from the Board of Directors after nearly a decade of service.

 

First Quarter 2023 Financial Results

•
Cash Position: Cash, cash equivalents and marketable securities were $1,889.5 million as of March 31, 2023, compared to $1,868.4 million as of December 31, 2022. The increase in cash of $21.1 million was primarily driven by the upfront payment received from Vertex in connection with a non-exclusive license agreement and a benefit from changes in net-working capital, offset by operating expenses.
•
Revenue: Total collaboration revenue was $100.0 million for the quarter ended March 31, 2023. Collaboration revenue for the first quarter of 2022 was not material. Collaboration revenue recognized in the first quarter of 2023 was primarily attributable to revenue recognized in connection with the upfront payment from Vertex.
•
R&D Expenses: R&D expenses were $99.9 million for the first quarter of 2023, compared to $118.2 million for the first quarter of 2022. The decrease in R&D expense was primarily driven by reduced variable external research and manufacturing costs.
•
G&A Expenses: General and administrative expenses were $22.4 million for the first quarter of 2023, compared to $28.0 million for the first quarter of 2022. The decrease in G&A expense was primarily driven by a decrease in external professional costs.
•
Collaboration Expense: Collaboration expense, net, was $42.2 million for the first quarter of 2023, compared to $30.6 million for the first quarter of 2022. The increase in collaboration expense, net, was primarily driven by an increase in manufacturing and pre-commercial costs associated with the exa-cel program.
•
Net Loss: Net loss was $53.1 million for the first quarter of 2023, compared to a net loss of $179.2 million for the first quarter of 2022.

 

About exagamglogene autotemcel (exa-cel)

Exa-cel, formerly known as CTX001, is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients with TDT or SCD characterized by recurrent vaso-occlusive crises (VOCs), in which a patient’s own hematopoietic stem cells are edited to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. The elevation of HbF by exa-cel has the potential to alleviate transfusion requirements for patients with TDT and reduce painful and debilitating sickle crises for patients with SCD. Earlier results from these ongoing trials were published in The New England Journal of Medicine in January of 2021.

 

Based on progress in this program to date, exa-cel has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for both TDT and SCD. Exa-cel has also been granted Orphan Drug Designation from the European Commission, as well as Priority Medicines (PRIME) designation from the European Medicines Agency (EMA), for both TDT and SCD. In the U.K., exa-cel has been granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) from the MHRA.


About CLIMB-111 and CLIMB-121

The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of exa-cel in patients ages 12 to 35 years with TDT or with SCD, characterized by recurrent VOCs, respectively. The trials are now closed for enrollment. Patients will be followed for approximately two years after exa-cel infusion. Each patient will be asked to participate in CLIMB-131, a long-term follow-up trial.

About CLIMB-131

This is a long-term, open-label trial to evaluate the safety and efficacy of exa-cel in patients who received exa-cel in CLIMB-111, CLIMB-121, CLIMB-141 or CLIMB-151. The trial is designed to follow participants for up to 15 years after exa-cel infusion.

About CLIMB-141 and CLIMB-151

The ongoing Phase 3 open-label trials, CLIMB-141 and CLIMB-151, are designed to assess the safety and efficacy of a single dose of exa-cel in patients ages 2 to 11 years with TDT or with SCD, characterized by recurrent VOCs, respectively. The trials are now open for enrollment and currently enrolling patients ages 5 to 11 years of age and will plan to extend to patients 2 to less than 5 years of age at a later date. Each trial will enroll approximately 12 patients. Patients will be followed for approximately two years after infusion. Each patient will be asked to participate in CLIMB-131, a long-term follow-up- trial.

About the CRISPR-Vertex Collaboration

CRISPR Therapeutics and Vertex Pharmaceuticals entered into a strategic research collaboration in 2015 focused on the use of CRISPR/Cas9 to discover and develop potential new treatments aimed at the underlying genetic causes of human disease. Exa-cel represents the first potential treatment to emerge from the joint research program. Under an amended collaboration agreement, Vertex now leads global development, manufacturing and commercialization of exa-cel and splits program costs and profits worldwide 60/40 with CRISPR Therapeutics.

About CTX110 and CTX112

CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR T investigational therapy targeting cluster of differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON clinical trial, which is designed to assess the safety and efficacy of CTX110 in adult patients with relapsed or refractory CD19-positive B-cell malignancies who have received at least two prior lines of therapy. CTX110 has been granted RMAT designation by the FDA. In addition, CTX112, a next-generation allogeneic CAR T cell therapy targeting CD19, is being investigated in a clinical trial. CTX112 includes two additional edits beyond CTX110 that are designed to enhance the potency of the CAR T cells.

About CTX130 and CTX131

CTX130, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR T investigational therapy targeting cluster of differentiation 70, or CD70, an antigen expressed on various solid tumors and hematologic malignancies. CTX130 is being investigated for the treatment of relapsed or refractory T-cell hematologic malignancies in the COBALT-LYM trial and for renal cell carcinoma in the COBALT-RCC trial. CTX130 has been granted Orphan Drug designation for the treatment of T cell lymphoma by the FDA and RMAT designation for the treatment of relapsed or refractory Mycosis Fungoides and Sézary Syndrome (MF/SS), types of cutaneous T cell lymphoma (CTCL). In addition, CTX131, a next-generation allogeneic CAR T cell therapy targeting CD70, is being assessed for safety and efficacy in a clinical trial investigating a basket of select solid tumors. CTX131 includes two additional edits beyond CTX130 that are designed to enhance the potency of the CAR T cells.

About VCTX210 and VCTX211

VCTX210 is an investigational, allogeneic, gene-edited, immune-evasive, stem cell-derived investigational therapy for the treatment of T1D. VCTX210 is being developed under a co-development and co-commercialization agreement between CRISPR Therapeutics and ViaCyte, Inc. VCTX211 is an allogeneic, gene-edited, stem cell-derived investigational therapy for the treatment of T1D, which incorporates additional gene edits that aim to further enhance cell fitness. This immune-evasive cell replacement therapy is designed to enable patients to produce their own insulin in response to glucose.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® standard character mark and design logo, COBALT™, CTX001™, CTX110®, CTX112™, CTX130™, CTX131™, CTX310™, VCTX210™, VCTX211™ are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

CRISPR Therapeutics Forward-Looking Statement

This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Kulkarni in this press release, as well as statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) its preclinical studies, clinical trials and pipeline products and programs, including, without limitation, the status of such studies and trials, regulatory filings for exa-cel and timing of data releases and regulatory submissions; (ii) potential benefits of exa-cel and the FDA’s review of the BLAs and impact of Priority Review on such timing; (iii) benefits of Dr. Prasad’s employment; (iv) the sufficiency of its cash resources; (v) benefits of its collaborations, including potential milestone payments and royalties on future products under the non-exclusive license agreement; and (vi) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for preliminary data from any clinical trial not to be indicative of final trial results; the potential that clinical trial results may not be favorable; that one or more of its internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for its product candidates; uncertainties inherent in the initiation and completion of preclinical studies for its product candidates and whether results from such studies will be predictive of future results of future studies or clinical trials; uncertainties about regulatory approvals to conduct trials or to market products; it may not realize the potential benefits of its collaborations; uncertainties regarding the intellectual property protection for its technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K, quarterly report on Form 10-Q and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

 

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com

 

CRISPR Therapeutics AG

Condensed Consolidated Statements of Operations

(Unaudited, In thousands except share data and per share data)

 

 

 

Three Months Ended March 31,

 

 

 

2023

 

 

2022

 

Revenue:

 

 

 

 

 

 

Collaboration revenue

 

$

100,000

 

 

$

178

 

Grant revenue

 

 

—

 

 

 

762

 

Total revenue

 

$

100,000

 

 

$

940

 

Operating expenses:

 

 

 

 

 

 

Research and development

 

 

99,935

 

 

 

118,245

 

General and administrative

 

 

22,360

 

 

 

28,021

 

Collaboration expense, net

 

 

42,192

 

 

 

30,646

 

Total operating expenses

 

 

164,487

 

 

 

176,912

 

Total operating expenses

 

 

(64,487

)

 

 

(175,972

)

Total other income, net

 

 

12,742

 

 

 

363

 

Net loss before income taxes

 

 

(51,745

)

 

 

(175,609

)

Provision for income taxes

 

 

(1,320

)

 

 

(3,608

)

Net loss before income taxes

 

 

(53,065

)

 

 

(179,217

)

Foreign currency translation adjustment

 

 

32

 

 

 

(27

)

Unrealized gain (loss) on marketable securities

 

 

6,227

 

 

 

(11,799

)

Comprehensive loss

 

$

(46,806

)

 

$

(191,043

)

Net loss per common share — basic

 

$

(0.67

)

 

$

(2.32

)

Basic weighted-average common shares outstanding

 

 

78,676,986

 

 

 

77,098,319

 

Net loss per common share — diluted

 

$

(0.67

)

 

$

(2.32

)

Diluted weighted-average common shares outstanding

 

 

78,676,986

 

 

 

77,098,319

 

 

 

CRISPR Therapeutics AG

Condensed Consolidated Balance Sheets Data

(Unaudited, in thousands)

 

 

 

As of

 

 

 

March 31, 2023

 

 

December 31, 2022

 

Cash and cash equivalents

 

$

344,407

 

 

$

211,885

 

Marketable securities

 

 

1,538,763

 

 

 

1,603,433

 

Marketable securities, non-current

 

 

6,320

 

 

 

53,130

 

Working capital

 

 

1,761,172

 

 

 

1,731,919

 

Total assets

 

 

2,244,364

 

 

 

2,243,057

 

Total shareholders' equity

 

 

1,854,896

 

 

 

1,875,479

 

 

 EX-101.PRE 3 crsp-20230508_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.LAB 4 crsp-20230508_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Address, City or Town Soliciting Material Amendment Flag Entity Incorporation, State or Country Code City Area Code Document Period End Date Entity Address, Postal Zip Code Entity File Number Entity Address, Address Line One Entity Tax Identification Number Entity Emerging Growth Company Entity Registrant Name Pre-commencement Tender Offer Title of 12(b) Security Document Type Written Communications Security Exchange Name Entity Address, Country Entity Central Index Key Local Phone Number Pre-commencement Issuer Tender Offer Cover [Abstract] Trading Symbol EX-101.SCH 5 crsp-20230508.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 08, 2023
Cover [Abstract]  
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001674416
Document Type 8-K
Document Period End Date May 08, 2023
Entity Registrant Name CRISPR THERAPEUTICS AG
Entity Incorporation, State or Country Code V8
Entity File Number 001-37923
Entity Address, Address Line One Baarerstrasse 14
Entity Address, Postal Zip Code 6300
Entity Address, City or Town Zug
Entity Address, Country CH
City Area Code 41 (0)41
Local Phone Number 561 32 77
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, nominal value CHF 0.03
Trading Symbol CRSP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 crsp-20230508_htm.xml IDEA: XBRL DOCUMENT 0001674416 2023-05-08 2023-05-08 false 00-0000000 0001674416 8-K 2023-05-08 CRISPR THERAPEUTICS AG V8 001-37923 Baarerstrasse 14 6300 Zug CH 41 (0)41 561 32 77 false false false false Common Shares, nominal value CHF 0.03 CRSP NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( ,* J%8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #"@*A6I';#1NX K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VVI:.CFHGA2$%Q0O(5D=C?8-"$9:??M3>MN%]$'\)B9/]]\ M ]/I(+2/^!Q]P$@6T]7D^B$)'3;L0!0$0-('="J5.3'DYLY'IR@_XQZ"TA]J MCU!S?@T.21E%"F9@$58BDYW10D=4Y.,);_2*#Y^Q7V!& _;H<* $55D!D_/$ M<)SZ#BZ &4887?HNH%F)2_5/[-(!=DI.R:ZI<1S+L5ER>8<*WIX>7Y9U"SLD M4H/&_"M90<> &W:>_-K621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M ,* J%9&YLB"300 (<0 8 >&PO=V]R:W-H965T&UL MG9AA;^(X$(;_BI633KM26^*0 NT!$J7M%NVVRQ%V5]K3?3") 6N3.&<[!?[] MC0--.#5,T/$!XL3SYLEX_,:FOY'JEUYS;L@VB5,]<-;&9+>ME@[7/&'Z2F8\ MA2M+J1)FH*E6+9TISJ(B*(E;GNMV6@D3J3/L%^>F:MB7N8E%RJ>*Z#Q)F-K= M\5AN!@YUWD[,Q&IM[(G6L)^Q%0^X^99-%;1:I4HD$IYJ(5.B^'+@C.CMG>?; M@*+'=\$W^NB8V$=92/G+-B;1P'$M$8]Y:*P$@Y]7/N9Q;)6 XY^#J%/>TP8> M'[^I/Q8/#P^S8)J/9?Q#1&8]<'H.B?B2Y;&9R$G$4T.Z="/ . 5[!O;]107G/#!OVE=P097N#FCTH M'K6(!CB1VE$)C(*K N+,\%Z&.239$)9&Y"$UPNS()-V/-F2MWS)P$]NU%1X$ M[_:"W@G!9[8C;N^">*[7_F]T"]!*/J_D\PJY]@FYL7SEBOPU6FBC8 3_K@/: M*_CU"K:L;W7&0CYPH&XU5Z_<&?[^&^VX?R!\[9*OC:D/#RF;LRV91)!'L11A MD3GRDB<+KNIX<477O73W'P3/+_%\5&P$8QL5X_L8LU4=#!Z_9+'F",=UR7%] M3IK&0*)8#!46\2WYS'=U1+@2Y(5VNKY/.PA6I\3JH&)E]<]W&:]CP<-[EY\1 MB&X)T3T/8LJ5D'861@3F0DC=RF'=M3W*X#&8M0&)&NR#,X MJ1(LKN7!51IY*I.GN!%/%;\,(3T\#?G^=0VK&E@6?ETN3PP@KM=$YE7>[N&V M_(YLHG4.9$V #;*-@)73>[@MSX6!UXY<$NI]6'PD 0]SJ+=:/VA0LO4)R]I@ M#3X/QI)*V(W 7'IE<<[)^.F1N%]^X:16;'37$@#^];B M<,T93 3; :XOI31O#;MY+?][&/X+4$L#!!0 ( ,* J%:?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( ,* MJ%:7BKL

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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports crsp-20230508.htm crsp-20230508.xsd crsp-20230508_lab.xml crsp-20230508_pre.xml crsp-ex99_1.htm http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "crsp-20230508.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "crsp-20230508.htm" ] }, "labelLink": { "local": [ "crsp-20230508_lab.xml" ] }, "presentationLink": { "local": [ "crsp-20230508_pre.xml" ] }, "schema": { "local": [ "crsp-20230508.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "crsp", "nsuri": "http://www.crisprtx.com/20230508", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230508.htm", "contextRef": "C_fcd84780-6d0f-4d15-9bd5-1233c52ac415", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "crsp-20230508.htm", "contextRef": "C_fcd84780-6d0f-4d15-9bd5-1233c52ac415", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.crisprtx.com/20230508/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0000950170-23-018790-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-018790-xbrl.zip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